收藏切换
A retrospective study on the efficacy and safety of nafamostat mesilate anticoagulation for patients treated with continuous renal replacement therapy in surgery intensive care unit
收藏切换
Yan ZHANG, Na YIN*, Haoshu DING*
World Clinical Drug | 2022, 43(9) : 1148 - 1153
Less
收藏切换
World Clinical Drug | 2022, 43(9): 1148-1153
• Article •
A retrospective study on the efficacy and safety of nafamostat mesilate anticoagulation for patients treated with continuous renal replacement therapy in surgery intensive care unit
Full
Yan ZHANG, Na YIN*, Haoshu DING*
Affiliations
  • Department of Anesthesiology and Surgical Intensive Care Unit, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
Published: 2022-09-10 doi: 10.13683/j.wph.2022.09.012
Outline
收藏切换
Objective

To evaluate the efficacy and safety of nafamostat mesilate anticoagulation in patients treated with continuous renal replacement therapy (CRRT) in surgery intensive care unit (SICU) by retrospective study.

Methods

From January 2021 to March 2022, patients who were admitted to the department of anesthesia and critical care medicine, Xinhua hospital affiliated to Shanghai Jiao Tong university and treated with CRRT, with nafamostat mesilate (anticoagulation group) and no heparin dialysis regimen (no heparin group) were enrolled. The filter life, filter replacement rate and the incidence of extracorporeal circuit thrombosis were analyzed. The disseminated intravascular coagulation (DIC) index, platelet count, hemoglobin level, electrolytes, the occurrence of gastrointestinal bleeding, hematuria, cerebral hemorrhage and other bleeding conditions before and after CRRT in the anticoagulation group was compared, and pay attention to the cost of hospitalization and other economic indicators.

Results

A total of 53 CRRT treatments were completed in 14 patients treated with nafamostat mesilate. A total of 67 CRRT treatments were completed in 19 patients with heparin-free anticoagulation regimen. The coagulation change rate of the filter and pipeline in the anticoagulation group was lower than that in the no heparin group (5.66% vs 17.91%, P<0.05), and the average use time of the filter was longer than that in the non-heparin group [(10.31±2.65) h vs (7.28±1.87) h, P<0.05]. The DIC index and platelet count before and after CRRT were not affected by nafamostat mesilate anticoagulation (P>0.05). In the anticoagulant group, hyperkalemia did not occur during CRRT, and the difference in serum potassium was statistically significant compared with that before treatment (P<0.05), while the difference in serum sodium and serum chloride was not statistically significant (P>0.05).

Conclusion

Nafamostat mesilate is a safe and effective anticoagulant for patients treated with CRRT in SICU.

nafamostat mesilate  /  anticoagulation  /  surgical intensive care unit  /  continuous renal replacement therapy
张艳, 殷娜, 丁皓姝. 甲磺酸萘莫司他抗凝对外科重症监护病房患者连续性肾脏替代治疗有效性及安全性回顾性研究. 世界临床药物, 2022 , 43 (9) : 1148 -1153 . DOI: 10.13683/j.wph.2022.09.012
Yan ZHANG, Na YIN, Haoshu DING. A retrospective study on the efficacy and safety of nafamostat mesilate anticoagulation for patients treated with continuous renal replacement therapy in surgery intensive care unit[J]. World Clinical Drug, 2022 , 43 (9) : 1148 -1153 . DOI: 10.13683/j.wph.2022.09.012
Year 2022 volume 43 Issue 9
7
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.09.012
  • Receive Date:2022-04-26
  • Online Date:2026-11-19
  • Published:2022-09-10
Article Data
Affiliations
History
  • Received:2022-04-26
  • Revised:2022-08-14
Affiliations
    Department of Anesthesiology and Surgical Intensive Care Unit, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.09.012
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT